Published: 2017-10-27

Introduction

Psoriasis

Efficacy and Safety of Apremilast in Patients with Moderate Plaque Psoriasis with Lower BSA (UNVEIL Phase IV Study)

Bruce Strober, Jerry Bagel, Mark Lebwohl, Linda Stein Gold, J Mark Jackson, Joana Goncalves, Eugenia Levi, Kristina Callis Duffin
| DOI https://doi.org/10.25251/skin.1.supp.10

Page s11

Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis

Andrew Blauvelt, Craig Leonardi, Claus Zachariae, Russel Burge, Terri Ridenour, Missy McKean-Matthews, Sandra Garces, Gregory Cameron
| DOI https://doi.org/10.25251/skin.1.supp.11

Page s12

Efficacy of Apremilast on Quality-of-Life Measures in Patients with Moderate Plaque Psoriasis (UNVEIL Phase IV Study)

Jerry Bagel, Mark Lebwohl, Linda Stein Gold, J Mark Jackson, Joana Goncalves, Eugenia Levi, Kristin Callis Duffin, Bruce Strober
| DOI https://doi.org/10.25251/skin.1.supp.12

Page s13

Evaluation of the PGAxBSA Composite Tool in Patients with Moderate-to-Severe Plaque Psoriasis

Kristina Callis Duffin, J Mark Jackson, Joana Goncalves, Eugenia Levi, Jerry Bagel
| DOI https://doi.org/10.25251/skin.1.supp.13

Page s14

First "Real-World" Insights on Apremilast Treatment for Patients with Plaque Psoriasis from the LAPIS-PSO Study: An Interim Analysis

Kristian Reich, Stefanie Bomas, Bernhard Korge, Maria Manasterski, Uwe Schwitchtenberg, Hannah Mentz, Kathrin Groegel
| DOI https://doi.org/10.25251/skin.1.supp.14

Page s15

Improvements in Lesional Pain and Itch Symptoms with Brodalumab in Psoriasis Studies

Lawrence F Eichenfield, April Armstrong, Lawrence Green, Shipra Rastogi, Radhakrishnan Pillai, Robert Israel
| DOI https://doi.org/10.25251/skin.1.supp.16

Page s17

Incidence of Inflammatory Bowel Disease Events in Adalimumab Clinical Trials Across Indications

Jeffrey R Curtis, Dirk Elewaut, Su Chen, Maja Hojnik, Navit Naveh, Jaclyn K Anderson
| DOI https://doi.org/10.25251/skin.1.supp.17

Page s18

Innovation in Topical Therapy for Psoriasis with Corticostereoid and Vitamin D Analogue Commbination

Siegfried Segaert, Neal Shear, Andrea Chiricozzi, Diamant Thaci, Jose M Carrascosa, Helen Young, Vincent Descamps
| DOI https://doi.org/10.25251/skin.1.supp.18

Page s19

Lack of Placental Transfer of Certolizumab Pegol During Pregnancy: Results from CRIB, a Prospective, Postmarketing, Multicenter, Pharmacokinetic Study

Alexa B Kimball, Xavier Mariette, Bincy Abraham, Ann Flynn, Frauke Forger, Anna Molto, Rene Marc Flipo, Astrid van Tubergen, Laura Shaughnessy, Jeff Simpson, Marie Teil, Eric Helmer, Maggie Wang, Eliza Chakravarty
| DOI https://doi.org/10.25251/skin.1.supp.20

Page s21

Neuropsychiatric Adverse Events in Brodalumab Psoriasis Studies

Mark Lebwohl, Kim A Papp, Jashin J Wu, Andrew Blauvelt, Alan Menter, Shipra Rastogi, Radhakrishnan Pillai, Robert Israel
| DOI https://doi.org/10.25251/skin.1.supp.24

Page s25

Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks

Desiree van der Heijde, Masato Okada, Chin Lee, Catherine L Shuler, Suchitrita Rathmann, Chen-Yen Lin, Philip J Mease
| DOI https://doi.org/10.25251/skin.1.supp.27

Page s28

Atopic Dermatitis

Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis

Eric Simpson, Andrew Bushmakin, Joseph C Cappelleri, Thomas Luger, Sonja Stander, Wynnis Tom, William C Ports, Anna M Tallman, Huaming Tan, Robert A Gerber
| DOI https://doi.org/10.25251/skin.1.supp.35

Page s36

Dupilumab with Concomitant Topical Corticosteroids in Atopic Dermatitis Patients who are Inadequately Controlled with or Medically Inadvisable for Cyclosporine A: a Phase 3 Clinical Trial (LIBERTY AD CAFE)

Marjolein de Bruin-Weller, Diamant Thaci, Catherine Smith, Allen Radin, Rick Zhang, Bolanle Akinlade, Abhijit Gadkari, Laurent Eckert, Thomas Hultsch, Gianluca Pirozzi, Neil MH Graham, Brad Shumel
| DOI https://doi.org/10.25251/skin.1.supp.36

Page s37

Dupilumab in Moderate-to-Severe Atopic Dermatitis: Pooled Efficacy Results from Two Identically Designed Randomized Phase 3 Trials (SOLO 1 & 2)

Carlos Ferrandiz, Pablo de la Cueva Dobao, Eric L Simpson, Rick Zhang, Abjijit Gadkari, Laurent Eckert, Bolanle Akinlade, Marius Ardeleanu
| DOI https://doi.org/10.25251/skin.1.supp.37

Page s38

The Effect of Crisaborole Ointment, 2%, on Pruritus in Patients with Atopic Dermatitis: An Extended Analysis

Gil Yosipovitch, Eric Simpson, Huaming Tan, Robert A Gerber, Thomas Luger, Sonja Stander, Wynnis Tom, Joseph C Cappelleri, Andrew G Bushmakin, William C Ports, Anna M Tallman
| DOI https://doi.org/10.25251/skin.1.supp.38

Page s39

Validation of the Severity of Pruritus Scale for the Assessment of Pruritus in Atopic Dermatitis

Gil Yosipovitch, Eric Simpson, Andrew G Bushmakin, Joseph C Cappelleri, Thomas Luger, Sonja Stander, Wynnis Tom, Katy Benjamin, William C Ports, Anna M Tallman
| DOI https://doi.org/10.25251/skin.1.supp.44

Page s45

Acne & Rosacea

Efficacy and Saftey of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Doxycycline in Subjects with Severe Inflammatory Acne (Non-Nodulocystic) that are Candidates for Oral Isotretinoin

James Del Rosso, Linda Stein Gold, Sandra Marchese Johnson, Maria Jose Rueda, Hilary Baldwin, Edward L Lain, Megan Landis, Marta Rendon, Emil Tanghetti, Jonathan Weiss
| DOI https://doi.org/10.25251/skin.1.supp.47

Page s48

Rapid Improvement with BPX-01 Minocycline Topical Gel in the Treatment of Moderate-to-Severe Inflammatory Acne Vulgaris: a Randomized, Double-Blind, Vehicle-Controlled Study

Andrew Alexis, James Del Rosso, Seemal R Desai, Jeanine Downie, Zoe D Draelos, Christina Feser, Rion Forconi, Joseph Fowler, Michael Gold, Joely Kaufman-Janette, Edward Lain, Mark Lee, Mark Ling, Ava Shamban, William Werschler, AnnaMarie Daniels
| DOI https://doi.org/10.25251/skin.1.supp.52

Page s53

Rosacea

Cosmetic

Efficacy and Safety of OnabotulinumtoxinA for Treatment of Moderate-to-Severe Forehead Lines

Steve Fagien, Joel Cohen, William Coleman, Gary Monheit, Jean Caruthers, Cheri Mao, Domenico Vitarella, Xiaofang Lei, Bhushan Hardas
| DOI https://doi.org/10.25251/skin.1.supp.71

Page s72

Efficacy and Safety of OnabotulinumtoxinA for Moderate-to-Severe Forehead Lines in Subjects with Upper Facial Lines

Koen De Boulle, Philip Werschler, Michael H Gold, Gerhard Sattler, Patricia Ogilvie, Cheri Mao, Domenico Vitarella, Xiaofang Lei, Bhushan Hardas
| DOI https://doi.org/10.25251/skin.1.supp.72

Page s73

Lip and Perioral Enhancement with HA Dermal Fillers in Individuals with Fitzpatrick Skin Types IV-VI

Susan C Taylor, Jeanine B Downie, Ava Shamban, Julius Few, Bashir Khan, Andrew Schumacher, Conor Gallagher
| DOI https://doi.org/10.25251/skin.1.supp.78

Page s79

Maximizing Pan-Facial Aesthetic Outcomes; Findings and Recommendations from the HARMONY Study

Michael Kaminer, Joel L Cohen, Vic Narurkar, Ava Shamban, Phil Werschler, Garrett T Shumate, Conor J Gallagher
| DOI https://doi.org/10.25251/skin.1.supp.79

Page s80

An Observational Study of the Safety and Efficacy of Tissue Stabilized-Guided Subcision to Improve the Appearance of Cellulite

Roy G Geronemus, Jeremy A Brauer, Suzanne L Kilmer, Simeon H Wall, Jr., Jeremy B Green, Joel L Cohen, Robert A Weiss, Tina S Alster, Michael S Kaminer
| DOI https://doi.org/10.25251/skin.1.supp.80

Page s81

Pan-facial Treatment Positively and Significantly Impacts Social Perception

Steven Dayan, Alexander Rivkin, Jonathan M Sykes, Craig F Teller, Susan H Weinkle, Garrett T Shumate, Conor J Gallagher
| DOI https://doi.org/10.25251/skin.1.supp.83

Page s84

Performance of a Facial Night Moisturizer for Redness-Prone Skin

Matthew H Meckfessel, Sandrine Teissedre, Nadege Lachmann, Francince Santoro
| DOI https://doi.org/10.25251/skin.1.supp.84

Page s85

VYC-17.5L is Effective for the Treatment of Static and Dynamic Radial Cheek Lines: Results from the BEAM Study

Patricia Ogilvie, Bernhard Fink, Christopher Leys, Sylvia Lipko-Godlewska, Francois Niforos, Graeme Kerson, Michael Silberberg
| DOI https://doi.org/10.25251/skin.1.supp.91

Page s92

Nail Unit Disorders

Adalimumab for Nail Psoriasis: Efficacy and Safety from the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial

Alice B Gottlieb, Boni E Elewski, Martin M Okun, Jerry Bagel, Yves Poulin, Yihua Gu, Ziqian Geng, David A Williams, Wendell C Valdecantos
| DOI https://doi.org/10.25251/skin.1.supp.96

Page s97

Improvement of Nail Psoriasis with Brodalumab in Phase 3 Trials

Mark G Lebwohl, Lawrence Green, Sylvia Hsu, Shipra Rastogi, Tina Lin, Radhakrishnan Pillai, Robert J Israel
| DOI https://doi.org/10.25251/skin.1.supp.98

Page s99

Hyperhidrosis

Open-Label Study (ARIDO) Evaluating Long-Term Safety of Topical Glycopyrronium Tosylate (GT) in Patients with Axillary Hyperhidrosis

Dee Anna Glaser, Adelaide A Hebert, Alexander Nast, William P Werschler, Stephen Shideler, Lawrence Green, Richard D Mamelok, Janice Drew, John Quiring, David M Pariser
| DOI https://doi.org/10.25251/skin.1.supp.94

Page s95

Disorders of Pigmentation

Melanoma

Non-Melanoma Skin Cancers and Benign Cutaneous Tumors

Daylight Photodynamic Therapy of Actinic Keratosis with BF-200 ALA compared to MAL

T Dirschka, S Ekanayake-Bohlig, R Dominicus, R Aschoff, E Herrera-Ceballos, R Botella-Estrada, A Hunfeld, B Schmitz, H Lubbert, S Puig
| DOI https://doi.org/10.25251/skin.1.supp.114

Page s115

Dermatologic Surgery and Wound Healing

Urticaria

Design and rational of the OPTIMA Study: Retreatment or Step-Up Therapy with Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU)

Gordon Sussman, Jacques Hebert, Wayne Gulliver, Charles Lynde, William H Yang, Olivier Chambenoit, Gretty Deutsch, Frederica DeTakacsy, Lenka Rihakova
| DOI https://doi.org/10.25251/skin.1.supp.124

Page s125

Omalizumab Retreatment of Patients swith Chronic Idopathic Urticaria/Spontaneous Urticaria (CIU/CSU) Following Return of Symptoms: Primary Results of the OPTIMA Study

Gordon Sussman, Jacques Hebert, Wayne Gulliver, Charles Lynde, William H Yang, Olivier Chambenoit, Antonio Vieira, Frederica De Takacsy, Lenka Rihakova
| DOI https://doi.org/10.25251/skin.1.supp.126

Page s127

Miscellaneous

Hidradenitis Suppurativa

Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER)

Christos C Zouboulis, Martin M Okun, Robert Gniadecki, Peter A Foley, Charles Lynde, Jamie Weisman, Piyalal Karunaratne, David A Williams
| DOI https://doi.org/10.25251/skin.1.supp.127

Page s128

Pediculosis

Abametapir Lotion, 0.74% Demonstrates High Elimination Rates of Head Lice with a Single Application in Phase 3 Trials

Lydie Hazan, Robert S Haber, Robert S Haber, Michael Husseman, Michael Husseman, Katie Shepherd, Katie Shepherd, Sharon Hanegraaf, Sharon Hanegraaf, Tina Ahveninen, Tina Ahveninen, Lisa Jenkins, Lisa Jenkins, Hugh Alsop, Hugh Alsop, Vernon M Bowles, Vernon M Bowles
| DOI https://doi.org/10.25251/skin.1.supp.130

Page s131